Screener
Halozyme Therapeutics HALO Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts receivable, net and contract assets | 455,827 | 441,273 |
| Inventories | 137,135 | 176,475 |
| Prepaid expenses and other current assets | 109,059 | 64,639 |
| Total current assets | 933,024 | 825,207 |
| Property and equipment, net | 84,271 | 82,137 |
| Prepaid expenses and other assets | 55,090 | 53,551 |
| Goodwill | 581,732 | 580,360 |
| Intangible assets, net | 922,443 | 981,467 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's total current assets?
- Halozyme Therapeutics (HALO) reported total current assets of $933.02M in Q2 2026.
- How has Halozyme Therapeutics's total current assets changed year-over-year?
- Halozyme Therapeutics's total current assets decreased by 16.9% year-over-year, from $1.12B to $933.02M.
- What is the long-term trend for Halozyme Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's total current assets has grown at a 8.3% compound annual growth rate (CAGR), from $554.76M to $825.21M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Halozyme Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude